$55.06
2.06% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Sanofi Sponsored ADR Stock price

$53.95
-2.57 4.55% 1M
-2.30 4.09% 6M
+5.72 11.86% YTD
+6.25 13.10% 1Y
+1.40 2.66% 3Y
+10.44 23.99% 5Y
+2.90 5.68% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.39 0.72%
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Key metrics

Market capitalization $132.07b
Enterprise Value $143.15b
P/E (TTM) P/E ratio 22.45
EV/FCF (TTM) EV/FCF 18.00
EV/Sales (TTM) EV/Sales 3.22
P/S ratio (TTM) P/S ratio 2.97
P/B ratio (TTM) P/B ratio 1.69
Dividend yield 3.78%
Last dividend (FY24) $2.04
Revenue growth (TTM) Revenue growth -4.57%
Revenue (TTM) Revenue $44.44b
EBIT (operating result TTM) EBIT $10.28b
Free Cash Flow (TTM) Free Cash Flow $7.95b
EPS (TTM) EPS $2.40
P/E forward 14.75
P/S forward 2.62
EV/Sales forward 2.84
Short interest 0.26%
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Sanofi Sponsored ADR forecast:

21x Buy
81%
4x Hold
15%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
81%
Hold
15%
Sell
4%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
44,435 44,435
5% 5%
100%
- Direct Costs 16,222 16,222
9% 9%
37%
28,213 28,213
2% 2%
63%
- Selling and Administrative Expenses 6,005 6,005
5% 5%
14%
- Research and Development Expense 7,998 7,998
10% 10%
18%
14,210 14,210
6% 6%
32%
- Depreciation and Amortization 3,927 3,927
25% 25%
9%
EBIT (Operating Income) EBIT 10,283 10,283
4% 4%
23%
Net Profit 6,015 6,015
3% 3%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Neutral
GlobeNewsWire
about 12 hours ago
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia  Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug d...
Neutral
GlobeNewsWire
6 days ago
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism helps reduce the frequency of bleeding episodes for people with hemophilia Paris, March 28, 2025...
Positive
Reuters
6 days ago
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 84,587
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today